Advertisement

Journal of Endocrinological Investigation

, Volume 40, Issue 11, pp 1243–1250 | Cite as

Levothyroxine monotherapy versus levothyroxine and selenium combination therapy in chronic lymphocytic thyroiditis

  • L. Yu
  • L. Zhou
  • E. Xu
  • Y. Bi
  • X. Hu
  • X. Pei
  • G. JinEmail author
Original Article

Abstract

Purpose

New strategies are needed for prevention and treatment of chronic lymphocytic thyroiditis (CLT). This study aimed to assess whether combination of levothyroxine treatment and selenium (Se) supplementation results in improved therapeutic effects in CLT compared with levothyroxine monotherapy.

Methods

An open-label, randomized controlled study was performed in 60 CLT patients assigned to two groups. Levothyroxine group (LT) patients (n = 24) received levothyroxine alone for 3 months; meanwhile, the combination (LTSS) group (n = 36) was administered levothyroxine with selenium yeast capsule. Blood selenium concentrations, anti-thyroid peroxidase (TPO) and anti-thyroglobulin (Tg) antibody levels, and inflammatory cytokine amounts were compared between both groups before and after treatment.

Results

At baseline, similar values were obtained in both groups for all the parameters assessed (p > 0.05). After treatment, significantly increased blood selenium levels (µg/L) [90.05 (80.69, 107.76) vs. 39.64 (29.42, 51.10), p < 0.001] and decreased anti-TPO antibody (23.63 ± 9.31 vs. 32.00 ± 10.41%, p = 0.002), anti-Tg antibody (35.84 ± 15.21 vs. 45.47 ± 14.24%, p = 0.015) and IL-2 amounts (pg/mL) [159.29 (124.54, 189.70) vs. 226.48 (190.74, 266.56), p < 0.001] were observed in the LTSS group compared with the LT group post-treatment; meanwhile, similar IL-10 concentrations [23.14 (21.65, 28.56) pg/mL vs. 24.68 (21.71, 29.67) pg/mL] were obtained in both groups. Subgroup analysis of patients with hypothyroidism showed the same trend observed in the whole population; in patients with normal thyroid function, only Se and IL-2 amounts differed between the two treatment groups. Correlation analysis of of the indexes: in HT patients, the basal serum selenium concentration was positively correlated with TT4 (r = 0.294, p < 0.05), significantly negatively correlated with TSH (r = −0.343, p < 0.01), and had no significant correlation with TT3 (p > 0.05).

Conclusions

These findings indicated that levothyroxine and selenium combination results in improved therapeutic effects than the levothyroxine monotherapy in preventing CLT progression.

Keywords

Selenium Levothyroxine Chronic lymphocytic thyroiditis Hypothyroidism IL-2 IL-10 

Notes

Compliance with ethical standards

Funding

This study was funded by the key projects of science and technology development fund of Bengbu medical college, China (Bykf12A12).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Clinical Research Ethical Committee of 1st affiliated Hospital of Bengbu Medical College.

Informed consent

Informed consent was provided by each participant.

References

  1. 1.
    Weetman AP (2013) The immunopathogenesis of chronic autoimmune thyroiditis one century after Hashimoto. Eur Thyroid J 1:243–250PubMedGoogle Scholar
  2. 2.
    Mazokopakis EE, Chatzipavlidou V (2007) Hashimoto’s thyroiditis and the role of selenium. Current concepts. Hell J Nucl Med 10:6–8PubMedGoogle Scholar
  3. 3.
    Michels AW, Eisenbarth GS (2010) Immunologic endocrine disorders. J Allergy Clin Immunol 125:S226–S237CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Carter Y, Sippel RS, Chen H (2014) Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management. Oncologist 19:34–43CrossRefPubMedGoogle Scholar
  5. 5.
    Ramesh BG, Bhargav PR, Rajesh BG, Vimala Devi N, Vijayaraghavan R, Aparna Varma B (2015) Genomics and phenomics of Hashimoto’s thyroiditis in children and adolescents: a prospective study from Southern India. Ann Transl Med 3:280–289PubMedPubMedCentralGoogle Scholar
  6. 6.
    Radetti G (2014) Clinical aspects of Hashimoto’s thyroiditis. Endocr Dev 26:158–170CrossRefPubMedGoogle Scholar
  7. 7.
    Zaletel K, Gaberscek S (2011) Hashimoto’s thyroiditis: from genes to the disease. Curr Genomics 12:576–588CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tan L, Sang ZN, Shen J, Wu YT, Yao ZX, Zhang JX, Zhao N, Zhang WQ (2013) Selenium supplementation alleviates autoimmune thyroiditis by regulating expression of TH1/TH2 cytokines. Biomed Environ Sci 26:920–925PubMedGoogle Scholar
  9. 9.
    Kucharska AM, Gorska E, Stelmaszczyk-Emmel A, Demkow U, Pyrzak B (2015) Immunological characteristics of children with Hashimoto’s autoimmune thyroiditis. Adv Exp Med Biol 833:47–53CrossRefPubMedGoogle Scholar
  10. 10.
    Demirbilek H, Kandemir N, Gonc EN, Ozon A, Alikasifoglu A (2009) Assessment of thyroid function during the long course of Hashimoto’s thyroiditis in children and adolescents. Clin Endocrinol (Oxf) 71:451–454CrossRefGoogle Scholar
  11. 11.
    Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM, Hofman A, Ross HA, Hooijkaas H, Tiemeier H, Bongers-Schokking JJ, Jaddoe VW, Visser TJ, Steegers EA, Medici M, Peeters RP (2013) Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: the generation R study. J Clin Endocrinol Metab 98:4382–4390CrossRefPubMedGoogle Scholar
  12. 12.
    Sgarbi JA, Kasamatsu TS, Matsumura LK, Maciel RM (2010) Parity is not related to autoimmune thyroid disease in a population-based study of Japanese-Brazilians. Thyroid 20:1151–1156CrossRefPubMedGoogle Scholar
  13. 13.
    Kohrle J (2015) Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 22:392–401CrossRefPubMedGoogle Scholar
  14. 14.
    Kohrle J (2013) Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 20:441–448CrossRefPubMedGoogle Scholar
  15. 15.
    Duntas LH (2015) The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res 47:721–726CrossRefPubMedGoogle Scholar
  16. 16.
    Sturniolo G, Mesa J (2013) Selenium supplementation and autoimmune thyroid diseases. Endocrinol Nutr 60:423–426CrossRefPubMedGoogle Scholar
  17. 17.
    Wu Q, Rayman MP, Lv H, Schomburg L, Cui B, Gao C, Chen P, Zhuang G, Zhang Z, Peng X, Li H, Zhao Y, He X, Zeng G, Qin F, Hou P, Shi B (2015) Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 100:4037–4047CrossRefPubMedGoogle Scholar
  18. 18.
    Drutel A, Archambeaud F, Caron P (2013) Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 78:155–164CrossRefGoogle Scholar
  19. 19.
    Ates I, Altay M, Yilmaz FM, Topcuoglu C, Yilmaz N, Berker D, Guler S (2016) The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis. Eur J Endocrinol 174:727–734CrossRefPubMedGoogle Scholar
  20. 20.
    Endocrinology branch of Chinese Medical Association” Chinese thyroid disease diagnosis and treatment guidelines” Editorial Committee (2008) Chinese guidelines of diagnosis and treatment of thyroid disease: thyroiditis. Chin J Int Med 47:784–788Google Scholar
  21. 21.
    Endocrinology branch of Chinese Medical Association” Chinese thyroid disease diagnosis and treatment guidelines” Editorial Committee (2007) The guidelines of diagnosis and treatment of thyroid disease: hypothyroidism. Zhonghua Nei Ke Za Zhi 46:967–971Google Scholar
  22. 22.
    Rasmussen LB, Schomburg L, Kohrle J, Pedersen IB, Hollenbach B, Hog A, Ovesen L, Perrild H, Laurberg P (2011) Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol 164:585–590CrossRefPubMedGoogle Scholar
  23. 23.
    Duntas LH, Benvenga S (2015) Selenium: an element for life. Endocrine 48:756–775CrossRefPubMedGoogle Scholar
  24. 24.
    Duntas LH (2010) Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 95:5180–5188CrossRefPubMedGoogle Scholar
  25. 25.
    Turker O, Kumanlioglu K, Karapolat I, Dogan I (2006) Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 190:151–156CrossRefPubMedGoogle Scholar
  26. 26.
    Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES (2007) Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto’s thyroiditis. Thyroid 17:609–612CrossRefPubMedGoogle Scholar
  27. 27.
    Zagrodzki P, Ratajczak R (2008) Selenium supplementation in autoimmune thyroiditis female patient–effects on thyroid and ovarian functions (case study). Biol Trace Elem Res 126:76–82CrossRefPubMedGoogle Scholar
  28. 28.
    Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D (2010) Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid 20:1163–1173CrossRefPubMedGoogle Scholar
  29. 29.
    De Farias CR, Cardoso BR, De Oliveira GM, De Mello Guazzelli IC, Catarino RM, Chammas MC, Cozzolino SM, Knobel M (2015) A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes. J Endocrinol Invest 38:1065–1074CrossRefPubMedGoogle Scholar
  30. 30.
    Duntas LH, Mantzou E, Koutras DA (2003) Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 148:389–393CrossRefPubMedGoogle Scholar
  31. 31.
    Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, Antoni A, Kletter K, Dudczak R, Willheim M (2008) No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 18:7–12CrossRefPubMedGoogle Scholar
  32. 32.
    Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C (2010) Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 73:535–539Google Scholar
  33. 33.
    Stazi AV, Trinti B (2010) Selenium status and over-expression of interleukin-15 in celiac disease and autoimmune thyroid diseases. Ann Ist Super Sanita 46:389–399PubMedGoogle Scholar
  34. 34.
    Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW (2002) Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 87:1687–1691CrossRefPubMedGoogle Scholar
  35. 35.
    Rayman MP (2004) The use of high-selenium yeast to raise selenium status: how does it measure up? Br J Nutr 92:557–573CrossRefPubMedGoogle Scholar
  36. 36.
    Anastasilakis AD, Toulis KA, Nisianakis P, Goulis DG, Kampas L, Valeri RM, Oikonomou D, Tzellos TG, Delaroudis S (2012) Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial. Int J Clin Pract 66:378–383CrossRefPubMedGoogle Scholar
  37. 37.
    Esposito D, Rotondi M, Accardo G, Vallone G, Conzo G, Docimo G, Selvaggi F, Cappelli C, Chiovato L, Giugliano D, Pasquali D (2017) Influence of short-term selenium supplementation on the natural course of Hashimoto’s thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J Endocrinol Invest 40:83–89CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2017

Authors and Affiliations

  • L. Yu
    • 1
  • L. Zhou
    • 2
  • E. Xu
    • 3
  • Y. Bi
    • 1
  • X. Hu
    • 1
  • X. Pei
    • 1
  • G. Jin
    • 1
    Email author
  1. 1.Department of EndocrinologyThe First Affiliated Hospital of Bengbu Medical CollegeBengbuChina
  2. 2.Department of EndocrinologyThe Second Affiliated Hospital of Bengbu Medical CollegeBengbuChina
  3. 3.Room of Physical DiagnosticsBengbu Medical CollegeBengbuChina

Personalised recommendations